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A B S T R A C T
Obesity is a well-established risk factor for atherosclerosis. However, the mechanistic link between accumula-
tion of adipose tissue and development of atherosclerosis is not clear. Adipose tissue comprises various depots
including white adipose tissue (WAT), brown adipose tissue (BAT) and thoracic and abdominal perivascular
adipose tissue (PVAT). The phenotype of thoracic PVAT resembles BAT, whereas abdominal PVAT is more like
WAT. Here, we review the distinct roles of the adipose tissue depots in the development of atherosclerosis with
the ultimate aim to understand how these can be targeted to reduce atherosclerosis. In obesity, increased fatty
acid release by WAT and decreased lipid combustion by BAT and thoracic PVAT lead to hyperlipidaemia, which
contributes to atherosclerosis development. Besides, obese WAT and abdominal PVAT release pro-inflamma-
tory factors that further promote atherosclerosis. To discourage atherosclerosis development, strategies that
reduce the release of pro-inflammatory factors and fatty acids from WAT and abdominal PVAT, or increase
combustion of fatty acids by activation of BAT and thoracic PVAT and beiging of WAT are probably most
efficient. Possible therapies could include anti-inflammatory compounds such as adiponectin and salicylates to
lower inflammation, and β3-adrenergic receptor activators to increase fatty acid combustion. Additional and
more specific strategies to promote fatty acid combustion are currently subject of investigation. In conclusion,
different adipose depots differentially affect atherosclerosis development, in which atherosclerosis is promoted
by energy-storing adipose depots and attenuated by energy-combusting adipose tissue. In obesity, combining
therapies that reduce inflammation and increase combustion of lipids are most conceivable to restrain
atherogenesis.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death world-
wide (Finegold et al., 2013), and atherosclerosis is the pathology
underlying most cardiovascular events. Obesity is a major risk factor
for CVD (Fox et al., 2008). However, the underlying biological
mechanism between accumulation of adipose tissue and atherosclero-
sis is not fully understood. Obesity is associated with hyperlipidaemia
(Klop et al., 2013; Nordestgaard, 2016) and systemic inflammation
(Hotamisligil, 2006; Shoelson et al., 2006), both of which are risk
factors for atherosclerosis. Nevertheless, distinct adipose tissue types
have specific functions that differentially influence atherosclerosis
development. More insight into the relation between adipose tissue
types and atherosclerosis will provide novel targets to treat (obese)
individuals with high risk of CVD. We therefore aim to review recent
advances in research on the role of different adipose tissue types, i.e.
white, brown and perivascular adipose tissue, in atherosclerosis, and
the ensuing therapeutic implications.
2. Atherosclerosis
2.1. Pathogenesis of atherosclerosis
The main risk factor for the development of atherosclerosis is
hypercholesterolemia. Atherosclerosis development is initiated by
enhanced retention of low-density lipoprotein (LDL) and very-low-
density lipoprotein (VLDL) remnant particles in the vessel wall. In
response, the vessel wall releases oxidative and inflammatory factors
that modify these particles, for example by oxidation, resulting in
oxidized LDL (oxLDL) (Hansson and Hermansson, 2011; Libby, 2002).
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LDL is also modified by hydrolysing enzymes that are present in the
lesions (Oorni et al., 2005; Wooton-Kee et al., 2004). Immune cells,
mainly monocytes, are recruited from the circulation upon the expres-
sion of chemoattractants like tumor necrosis factor (TNF) and mono-
cyte chemoattractant protein-1 (MCP-1) in the lesions (Libby et al.,
2013). The recruited monocytes maturate into macrophages and
scavenge the accumulating and modified lipoproteins thereby develop-
ing into foam cells. Foam cells augment the inflammatory response,
resulting in additional recruitment of immune cells into the athero-
sclerotic plaque (Hansson and Hermansson, 2011; Libby, 2002). While
the atherosclerotic plaque grows and a necrotic core forms, the
endothelial cap destabilizes. In an attempt to stabilize this cap, smooth
muscle cells proliferate from the media into the intima and produce
collagen and elastin. Once the balance is in favour of destabilizing
factors the cap may rupture, potentially leading to a cardiovascular
event (Libby et al., 2013).
In many cell types involved in build-up of the atherosclerotic
plaque, intracellular inflammatory pathways control the expression of
adhesion molecules and inflammatory chemokines and cytokines.
Besides local inflammation in the vasculature, other peripheral sources
of inflammation can augment the development of atherosclerosis,
including chronic infection, autoimmune diseases (Khovidhunkit
et al., 2004; van Diepen et al., 2013), hepatic inflammation (Wong
et al., 2012) and obesity (Shoelson et al., 2006).
2.2. Triglyceride-rich lipoproteins and atherosclerosis
Novel insights from epidemiological and genetic studies suggest
that elevated levels of triglyceride-rich lipoproteins (i.e. chylomicrons
and VLDL), which mainly carry triglycerides in addition to some
cholesterol, are a causal risk factor for atherosclerosis (Kannel and
Vasan, 2009; Nordestgaard and Varbo, 2014). This notion is under-
scored by preclinical data showing that reduction of triglyceride-rich
lipoproteins by enhancing lipoprotein lipase (LPL)-mediated lipolysis
decreases atherosclerosis development. For example, enhancing LPL
activity by apoA5 overexpression lowers plasma triglycerides without
affecting cholesterol in wild-type mice (Pennacchio et al., 2001) and
protects against atherosclerosis in Apoe-/- mice (Grosskopf et al.,
2012). In contrast to cholesterol, most cells in the body can metabolize
triglycerides. Also, unlike cholesterol, there is no build-up of triglycer-
ides in the atherosclerotic plaque (Nordestgaard, 2016). However,
removal of triglycerides from circulating triglyceride-rich lipoproteins
by LPL in peripheral organs and exchange of triglycerides from VLDL
for cholesteryl esters from high-density lipoproteins (HDL) by choles-
teryl ester transfer protein (Karalis et al., 2013) results in formation of
atherogenic cholesterol-enriched remnant particles (Berbée et al.,
2015; Dong et al., 2013). Therefore, plasma triglycerides may merely
reflect the presence of lipoprotein abnormalities such as increased
cholesterol-enriched remnant particles, which are the actual inducers
of atherogenic disease (Goldberg et al., 2011).
Several hypotheses exist on how triglyceride-rich lipoproteins
themselves induce atherogenesis (Goldberg et al., 2011). One of them
states that postprandially, chylomicrons are converted to remnants
which can infiltrate the vessel wall and deposit cholesterol (Zilversmit,
1973). Although proving this is complicated, data from several studies
combined, as reviewed by Goldberg et al. (2011), indicate that large
triglyceride-rich lipoproteins are able to deposit cholesterol in the
vessel wall and thus have direct atherogenic properties, although they
are not nearly as atherogenic as smaller lipoproteins are. Besides, it is
postulated that triglycerides in the arterial intima are hydrolysed, e.g.
by LPL that is expressed by macrophages, which results in release of
free fatty acids and monoacylglycerols. In vitro, these factors promote
coagulation and induce expression of adhesion molecules and inflam-
mation, indicating that lipolysis of triglyceride-rich lipoproteins in the
vessel wall leads to local and systemic low-grade inflammation
(Goldberg et al., 2011; Nordestgaard, 2016). Moreover, VLDL and its
remnants contain apoCI and apoCIII. In addition to inhibition of the
clearance of these lipoproteins from plasma (Berbée et al., 2005;
Gordts et al., 2016), they have pro-inflammatory properties. For
example, apoCI enhances lipopolysaccharide-induced inflammation
(Berbée et al., 2006) and lipopolysaccharide-induced atherosclerosis
development (Westerterp et al., 2007). ApoCIII activates pro-inflam-
matory pathways in endothelial cells and macrophages, thereby
promoting an atherogenic inflammatory cascade (Kawakami et al.,
2006a, 2006b).
Taken together, triglyceride-rich lipoproteins contribute to athero-
sclerosis by being precursors for cholesterol-enriched remnant parti-
cles that deposit cholesterol in the vessel wall and by promoting
inflammation by carrying apoCI and apoCIII and releasing lipolysis
products, although all of these mechanisms would be hard to prove
experimentally.
3. Adipose tissue types
Adipose tissue is the main site for energy storage and it is found
throughout the body in distinct subcutaneous and visceral depots. It is
mainly composed of adipocytes, which come in different natures, i.e.
white, beige and brown adipocytes. The relative amount of these cell
types present in a specific adipose tissue depot defines its colour.
Adipose tissue is highly plastic and brown adipocytes can adopt a
whiter phenotype (Shimizu et al., 2014) and beige and white adipocytes
are able to transdifferentiate into one another (Rosenwald et al., 2013).
Therefore, borders between distinct depots are not clear-cut and the
existence of a single adipose organ existing of varying depots is often
advocated (Cinti, 2005). However, as classification of the depots within
the adipose organ is helpful to describe molecular findings, the main
adipose tissue depots are classified as white adipose tissue (WAT),
brown adipose tissue (BAT) and perivascular adipose tissue (PVAT).
Although these adipose tissue depots all contribute to clearance of
(postprandial) triglyceride-rich lipoproteins by hydrolysing their tri-
glycerides through the activity of LPL, subsequent lipid handling
markedly differs between the prevailing adipocyte types in the depot.
This is due to the fact that the white, beige and brown adipocytes have a
distinct morphology and physiology (Cinti, 2009; Puigserver and
Spiegelman, 2003).
3.1. White adipose tissue
WAT is the most abundant adipose tissue type, found throughout
the body in different subcutaneous and visceral depots (Cinti, 2005).
WAT is a major participant in energy regulation of the body by storing
excess ingested fatty acids in the form of triglycerides in the adipocytes
and by releasing fatty acids (by intracellular lipolysis) to meet the
energy needs of other organs. It is also an endocrine organ controlling
essential metabolic processes, including lipid and glucose homeostasis
(Kershaw and Flier, 2004). The spherical adipocytes characteristically
contain a single large lipid droplet and a few mitochondria that are
dispersed in a thin surrounding layer of cytoplasm.
3.2. Brown and beige adipose tissue
BAT is found in the neck, above the claviculae and around the spine
in humans (Cypess et al., 2009; van Marken Lichtenbelt et al., 2009;
Virtanen et al., 2009). In contrast to WAT, which stores energy, BAT
combusts fatty acids to generate heat and maintain body temperature,
which is defined as non-shivering thermogenesis. Hence brown adipo-
cytes, that are smaller than white adipocytes, contain many mitochon-
dria and typically hold multiple small lipid droplets (Cinti, 2009).
Catecholamines induce thermogenesis and signal via all types of
adrenergic receptors including β1, β2, β3, α1 and α2, although not
all of these have stimulatory effects on thermogenesis. Expression of
the stimulatory β3-adrenergic receptor on brown adipocytes is likely
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the most specific and relevant for heat production. Apart from
adrenergic receptor expression, thermogenesis is dependent on intra-
cellular lipolysis and the presence of uncoupling protein 1 (UCP1).
Intracellular lipolysis yields fatty acids, which are used as substrates for
heat production (Cannon and Nedergaard, 2004). UCP1 resides in the
inner mitochondrial membrane and facilitates proton leak, thereby
disturbing the proton gradient. This “uncouples” electron transport
from synthesis of ATP and leads to production of heat (Cannon and
Nedergaard, 2004; Fedorenko et al., 2012). It is known that besides
classical brown adipocytes with high UCP1 expression, brown-like cells
with very low basal but highly inducible UCP1 expression exist. These
cells usually reside in WAT and are called beige adipocytes (Wu et al.,
2012).
3.3. Perivascular adipose tissue
Mammals also have PVAT, which is distinct from WAT and BAT
due to its specific location and function. PVAT surrounds systemic
blood vessels with the exception of the cerebral region. PVAT's main
function is to provide mechanical support to the vessels and to regulate
vascular tension and torsion (Soltis and Cassis, 1991). One way by
which PVAT exerts its function is by releasing biologically active
molecules that have paracrine effects on the vessels (Lohn et al.,
2002). Human PVAT (peritibial and popliteal artery) has a less
inflammatory phenotype compared to subcutaneous WAT from the
same region (Mauro et al., 2013). However, the phenotype of PVAT
depends on its location in the body, as dissimilar kinds of PVAT have
been found in thoracic and abdominal regions. Abdominal PVAT has
been proposed to have characteristics mostly resembling WAT,
whereas thoracic PVAT has more characteristics of BAT (Fitzgibbons
et al., 2011; Padilla et al., 2013). Histology and electron microscopy
analyses indicated structural similarities between abdominal PVAT and
visceral WAT (Padilla et al., 2013). On the other hand, microarray
analysis in mice revealed that BAT and thoracic PVAT have virtually
identical global gene expression patterns with equally high expression
of Ucp1, Cidea, and other genes known to be uniquely or very highly
expressed in BAT (Fitzgibbons et al., 2011). Electron microscopy
confirmed that thoracic PVAT contains multilocular lipid droplets
and abundance of mitochondria, and for that reason resembles BAT
(Fitzgibbons et al., 2011; Padilla et al., 2013). Abdominal PVAT thus
seems to mainly store lipids whereas thoracic PVAT mainly burns
lipids. One could speculate that thoracic PVAT has this lipid-burning
and heat-generating function because of its proximity near the body's
main vessels, which makes efficient transportation of heat throughout
the body possible.
4. White adipose tissue and atherosclerosis
Under healthy conditions, WAT acts as a lipid sink by storing lipids,
which prevents lipids to accumulate in the circulation and therefore has
anti-atherogenic effects (Fig. 1). In contrast, during obesity, WAT
expansion leads to dysfunctional WAT that renders the circulating lipid
profile pro-atherogenic, as will be explained below. WAT mass is
determined by the triglyceride turnover within this tissue, i.e. the
balance between triglyceride storage and triglyceride removal from
adipocytes. This process is dynamic: Arner et al. (2011) (Spalding et al.,
2008) showed that during the average ten-year lifespan of human
subcutaneous white adipocytes, the triglyceride pool is renewed six
times. In obesity, the triglyceride turnover in subcutaneous white
adipocytes is decreased due to a combination of increased storage
and decreased removal of triglycerides (Arner et al., 2011; Ryden et al.,
2013).
The removal of triglycerides from white adipocytes is dependent on
the process of intracellular lipolysis, in which triglycerides are broken
down and fatty acids are released from the white adipocytes. These
fatty acids are subsequently oxidized in other organs such as muscle,
liver and BAT. Obesity is characterized by elevated plasma levels of free
fatty acids, which is explained by the fact that white adipocytes have a
basal intracellular lipolytic rate (i.e. spontaneous, unstimulated lipo-
lysis), which increases with larger fat cell size (Ryden and Arner, 2007).
Since obesity is characterized by hypertrophy of white adipocytes,
obesity results in an elevated basal lipolytic rate and thus augmented
release of fatty acids (Langin and Arner, 2006). Consequently, accu-
mulation of fatty acids in plasma occurs (Fig. 1). Intracellular lipolysis
within adipocytes can also be stimulated acutely via sympathetic
innervation or hormones (i.e. by the catecholamines noradrenaline
and adrenaline) (Bartness et al., 2010). The lipolytic responsiveness to
catecholamines is dependent on the adipose tissue depot in which the
white adipocytes are situated: visceral white adipocytes have higher
catecholamine-induced lipolysis than subcutaneous white adipocytes
(van Harmelen et al., 2002, 1997). In obesity, the responsiveness of
visceral white adipocytes to catecholamines is higher due to increased
β-adrenoceptor sensitivity of these cells (Hoffstedt et al., 1997), which
results in more fatty acid release. In contrast, subcutaneous white
adipocytes have a reduced response to catecholamines in obesity
(Langin et al., 2005). Therefore, the elevated fatty acid plasma levels
observed in obesity cannot be explained by the catecholamine-induced
lipolysis of subcutaneous white adipocytes.
Intracellular lipolysis in white adipocytes is inhibited by insulin.
The responsiveness of white adipocytes to insulin is also dependent on
the adipose tissue depot in which they reside; insulin-induced inhibi-
tion of lipolysis is lower in visceral as compared to subcutaneous white
adipocytes (Zierath et al., 1998). This suggests that visceral adipose
tissue already releases more fatty acids than subcutaneous adipose
tissue in the insulin-sensitive, non-obese state. Nevertheless, both
visceral and subcutaneous white adipocytes become resistant to the
anti-lipolytic effect of insulin in obesity (Jensen et al., 1989), which
possibly contributes to an increased release of fatty acids by both types
of white adipocytes in obesity. Taken together, white adipocytes release
more fatty acids in obesity due to increased basal lipolysis and
resistance to insulin. Visceral white adipocytes exhibit increased
catecholamine-stimulated lipolysis during obesity, which even further
elevates fatty acid release. This increased release of fatty acids by
visceral white adipocytes is important, since a substantial part of WAT
is situated in the visceral region, making up ~10% of total fat mass.
Indeed, a strong link exists between large amounts of visceral adipose
tissue and development of cardiovascular disease (Kim et al., 2015).
WAT lipolysis and the subsequent rise in circulating free fatty acid
levels contribute to the development of hypertriglyceridemia and is at
least in part explained by the fact that fatty acids serve as substrate for
hepatic VLDL-triglyceride production (Kissebah et al., 1974). Fatty
acids released by visceral adipose tissue are directly conducted to the
liver via the portal vein (Ebbert and Jensen, 2013). Additionally,
elevated circulating fatty acids induce insulin resistance in peripheral
organs, which leads to decreased fatty acid oxidation and therefore
reduced clearance of fatty acids from the circulation by these organs
(Abate et al., 1995; Frayn, 2000). This cascade leads to a further
increase of hepatic VLDL-triglyceride production and is augmented
when fatty acids are deposited ectopically in muscle or liver, where they
cause even more insulin resistance (Wueest et al., 2016).
Fatty acids are not only substrates for energy metabolism, but,
dependent on the type of fatty acid, are also actively involved in
modulating several signalling pathways that mediate inflammation in
cells involved in atherosclerosis development. For instance, fatty acids
can activate the Toll-like receptors TLR2 and TLR4, which activates
NF-κB signalling in macrophages (Lee et al., 2004; Shi et al., 2006).
Besides releasing fatty acids, white adipocytes secrete a wide range of
pro-inflammatory factors such as adipokines, classical cytokines and
chemokines (Cao, 2014). WAT is infiltrated by several types of immune
cells both under lean and obese conditions as recently reviewed (Exley
et al., 2014; Grant and Dixit, 2015). Adipocyte hypertrophy is
associated with upregulation of JNK and NF-κB signalling pathways,
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oxidative stress, ER stress, increased release of pro-inflammatory
adipokines and chemokines and apoptotic signalling in the adipocytes
(Hotamisligil, 2005, 2006). As a consequence, pro-inflammatory im-
mune cells are attracted towards WAT (Weisberg et al., 2003; Xu et al.,
2003), which also secrete inflammatory factors. During WAT expansion
in obesity, the number of pro-inflammatory M1 type macrophages,
cytotoxic T cells, Th1 cells, B cells and mast cells increase, whereas the
anti-inflammatory M2 type macrophages, regulatory T cells and
eosinophils decrease (Schipper et al., 2012). Obese adipose tissue is
characterized by chronic local inflammation and the presence of crown-
like structures (i.e. macrophages that surround hypertrophic, stressed
and apoptotic adipocytes) (Cinti et al., 2005; Murano et al., 2008).
Obesity eventually leads to systemic inflammation, characterized by
increased levels of activated circulating immune cells, elevated levels of
pro-inflammatory adipokines (e.g. leptin), and cytokines (i.e. elevation
of TNF, IL-1Ra and IL-6), as well as increased CRP in the circulation
(Karalis et al., 2009; Visser et al., 1999).
Many types of adipokines released by WAT have immunomodula-
tory properties or have direct effects on the vascular wall. For instance,
leptin has been shown to promote smooth muscle cell migration
(Trovati et al., 2014) and to induce the generation of reactive oxygen
species (ROS) and MCP-1 expression in endothelial cells (Bouloumie
et al., 1999). In addition, apoE-deficient mice treated with leptin show
increased atherosclerosis development (Bodary et al., 2005). Other
pro-inflammatory adipokines that may stimulate the progression of
atherosclerotic plaques are resistin, visfatin and apelin (Maresca et al.,
2015), all of which are increased in obesity. Some adipokines, like
adiponectin and omentin, have a protective role in atherosclerosis
development (Ghantous et al., 2015; Tan et al., 2015). For instance,
apoE/adiponectin double-deficient mice show accelerated atherogen-
esis and adenoviral expression of human adiponectin in Apoe-/- mice
attenuates the development of atherosclerosis (Okamoto et al., 2002).
Transgenic overexpression of human omentin in adipocytes of Apoe-/-
mice suppresses atherosclerosis development (Hiramatsu-Ito et al.,
2016). Of note, circulating levels of both adiponectin and omentin are
reduced with increased adiposity. Thus, by secreting elevated levels of
pro-inflammatory adipokines or reduced levels of anti-inflammatory
adipokines, WAT participates adversely in the progression of athero-
sclerosis development in obesity (Fig. 1). It remains to be investigated
whether pro-inflammatory adipokines are able to initiate the process of
atherosclerosis or whether they merely modulate atherosclerosis
progression.
5. Brown adipose tissue and atherosclerosis
In contrast to WAT, which likely contributes to atherosclerosis as
Fig. 1. The role of white, brown and perivascular adipose tissues in the development of atherosclerosis during obesity, and treatment strategies. In obesity, both energy storage and fatty
acid release are enhanced in white adipose tissue (WAT). Immune cells infiltrate the WAT and abdominal perivascular adipose tissue (PVAT), causing systemic inflammation. Brown
adipose tissue (BAT) and thoracic PVAT display a whitened phenotype in obesity, resulting in decreased combustion of fatty acids. Therapeutic strategies targeting the adipose tissue
depots to reduce atherosclerosis development should focus on recruitment and activation of brown adipocytes to increase combustion of fatty acids in BAT and thoracic PVAT. Also,
beiging of adipocytes in WAT to increase fatty acid combustion would contribute to reduced circulating triglyceride-rich lipoproteins and their remnants. This should be combined with
anti-inflammatory therapies to decrease systemic inflammation and ultimately reduce atherosclerosis. WAT, white adipose tissue; PVAT, perivascular adipose tissue; BAT, brown
adipose tissue; FA, fatty acid; TRL, triglyceride-rich lipoprotein.
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mentioned above, BAT is increasingly recognized as a potential target
to reduce atherosclerosis development. BAT has an important role in
lipoprotein metabolism, as thermogenesis consumes large amounts of
fatty acids (Fig. 1). When intracellular lipid stores are depleted, BAT
takes up glucose as well as triglyceride-derived fatty acids from
triglyceride-rich lipoproteins from the blood. Glucose is likely used
for de novo lipogenesis and fatty acids are stored in the lipid droplets as
triglycerides before they are used for oxidation in the mitochondria
(Hoeke et al., 2016).
In 2011, Bartelt et al. (2011) were the first to show that activation of
BAT by cold exposure significantly reduces plasma triglyceride levels of
hyperlipidemic Apoa5-/- mice. Subsequently, it was demonstrated that
active BAT takes up plasma triglycerides mostly after lipolysis (Khedoe
et al., 2015), which is in line with the fact that LPL activity and the
presence of CD36 are crucial for the clearance of triglycerides by BAT
(Bartelt et al., 2011). The potential of BAT to alleviate hypertriglycer-
idemia was reinforced by several studies in which BAT activation
reduces plasma triglyceride levels (Boon et al., 2014; Geerling et al.,
2014; Sun et al., 2014; van Dam et al., 2015). Only recently, it was
shown that activated BAT also protects from atherosclerosis develop-
ment in mice (Berbée et al., 2015). More specifically, activation of BAT
by β3-adrenergic receptor stimulation in hyperlipidemic APOE*3-
Leiden. CETP mice, a well-established model for human-like lipopro-
tein metabolism (de Haan et al., 2008; Westerterp et al., 2006), not
only lowers plasma triglycerides but also cholesterol levels. BAT itself is
responsible for the uptake of triglyceride-derived fatty acids, leading to
the formation of cholesterol-enriched lipoprotein remnants, which are
subsequently cleared from the plasma by the liver via binding of apoE
to the hepatic LDL receptor (LDLR). Ultimately, the lower plasma
cholesterol levels result in reduced atherosclerosis (Berbée et al.,
2015). An intact apoE-LDLR clearance pathway is critical for this
effect, evidenced by the fact that BAT activation neither lowers
cholesterol levels nor reduces atherosclerosis development in Apoe-/-
or Ldlr-/-mice (Berbée et al., 2015; Dong et al., 2013). Vice versa, BAT
dysfunction aggravates atherosclerosis as was shown in a model where
lipoatrophic BAT was generated by knocking out the insulin receptor in
BAT in Apoe-/- mice. Although these mice exhibit similar plasma
cholesterol levels, they have higher plasma triglycerides and increased
atherosclerosis development. Increased inflammation might underlie
this phenotype as Apoe-/- mice with lipoatrophic BAT exhibited higher
pro-inflammatory marker expression in adipose tissues and increased
macrophage infiltration in the aortic root than Apoe-/- mice (Gomez-
Hernandez et al., 2016).
While most data on the role of BAT in atherosclerosis development
were obtained in rodents, some evidence exists for similar beneficial
effects of BAT activation in humans. For instance, daily cold exposure
for 20 min for 90 days reduces total cholesterol and LDL-cholesterol in
hypercholesterolemic individuals (De Lorenzo et al., 1998). A more
recent study showed that cold exposure increases lipid turnover and
oxidation in overweight and obese men, possibly to fuel active brown
adipocytes (Chondronikola et al., 2016). Moreover, BAT activity as
measured by 18F-FDG uptake is associated with reduced risk of
cardiovascular events (Takx et al., 2016).
Besides merely reducing plasma lipids due to enhanced lipoprotein
clearance, BAT activation also alters lipid distribution between adipose
tissue depots because fatty acids are shuttled to the brown adipocytes
as substrates for generation of heat while white adipocytes provide
these lipids. Remarkably, LPL expression in BAT is a stronger
determinant of plasma lipid levels than LPL in WAT, since deficiency
of LPL in the entire adipose tissue increases plasma triglycerides
particularly by reducing lipid uptake in BAT (Bartelt et al., 2013;
Garcia-Arcos et al., 2013). The altered distribution of fatty acids
between BAT and WAT during cold exposure is dependent on the
regulation of LPL activity by Angptl4 (Dijk et al., 2015) and strengthens
the idea that BAT not only lowers plasma lipid levels, but also reduces
fat storage in WAT. Indeed, several studies show reduced fatty acid
uptake by WAT or lower WAT mass upon activation of BAT (Boon
et al., 2014; van Dam et al., 2015). Some BAT activators lead to
increased fatty acid uptake in WAT even though WAT shrinks, which is
likely due to beiging of this depot by these activators (Bartelt et al.,
2011; Berbée et al., 2015; Kooijman et al., 2015). In humans, it has
also been shown that 6 weeks of cold exposure (i.e. 17 °C for 2 h/day)
reduces body fat mass (Yoneshiro et al., 2013). Overall, BAT activation
discourages fat storage in WAT, thereby also indirectly contributing to
improved cardiometabolic health.
Whether BAT affects the immunological aspect of atherosclerosis is
a field scantily studied. Recent research mostly focused on immunolo-
gical pathways that mediate brown and beige adipocyte development
and function and this has been reviewed by van den Berg et al. (2016).
BAT does contain immune cells (macrophages) (Nguyen et al., 2011)
and also secretes cytokines (e.g. IL-6). Although the transcript levels of
pro-inflammatory cytokines in BAT are lower compared to WAT,
augmented expression of pro-inflammatory cytokines has been found
in obese BAT. These pro-inflammatory factors are thought to diminish
BAT function (Villarroya et al., 2016), which could result in reduced
combustion of plasma lipids by BAT and thereby promote athero-
sclerosis development. Besides, release of pro-inflammatory factors
contributes to systemic inflammation, which also stimulates athero-
genesis. Interestingly, housing of obese mice at thermoneutrality,
which renders BAT inactive, results in increased inflammation in
gonadal WAT, BAT and in the vasculature, and enhanced development
of atherosclerosis (Tian et al., 2016). Whether BAT activation also
protects from atherosclerosis by decreasing inflammation remains to
be investigated. Of note, in humans, 18F-FDG uptake within BAT
negatively correlates with arterial inflammation, suggesting that BAT
activity negatively relates to arterial inflammation (Takx et al., 2016).
Obesity is associated with a reduced BAT function, evidenced by
lipid accumulation and mitochondrial dysfunction and loss, i.e.
“whitening” (Hung et al., 2014; Sanchez-Gurmaches et al., 2016;
Shimizu et al., 2014) (Fig. 1). Therefore, it is possible that in an obese
and/or unhealthy state, dysfunctional BAT further contributes to
hyperlipidaemia and atherosclerosis instead of counteracting plaque
development. Given the fact that obesity is a prominent risk factor for
CVD (Fox et al., 2008), future research should focus on the potential to
activate BAT in obese individuals, despite its whitened phenotype.
6. Perivascular adipose tissue and atherosclerosis
PVAT is in direct contact with the adventitia of the vessels without
any organized barrier to separate the two, suggesting that PVAT has a
direct local role in atherosclerosis development. Due to its direct
contact, the paracrine effects of PVAT on vessel walls are probably
stronger than potential effects of factors released by WAT. PVAT
adipocytes, immune cells and fibroblasts all release vasoactive mole-
cules such as NO, angiotensin, leptin and adiponectin, which have a net
anti-contractile effect under healthy conditions. PVAT also releases
adipocyte derived relaxing factor (ADRF), which counteracts vasocon-
striction and thereby regulates vascular tone (Lohn et al., 2002).
Like the other adipose tissues, PVAT expands in obesity. As a result,
PVAT becomes dysfunctional, which is characterized by hypoxia,
infiltration of immune cells (monocytes, lymphocytes and granulo-
cytes) and production of pro-inflammatory adipokines, cytokines and
chemokines (Greenstein et al., 2009; Henrichot et al., 2005; Police
et al., 2009). High-fat diet-feeding (Chatterjee et al., 2009) and
hypercholesterolemia without obesity (Lohmann et al., 2009) increase
inflammation in PVAT. This inflammation may propagate to the
underlying vessel wall, causing local smooth muscle cell and endothe-
lial dysfunction, ultimately contributing to atherosclerosis development
(Lee et al., 2014; Wang et al., 2009). Moreover, the protective anti-
contractile properties of PVAT which are present in a healthy state are
abolished in obese patients (Greenstein et al., 2009). Recently, Zou
et al. (2016) provided direct evidence that dysfunctional PVAT is linked
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to vascular dysfunction and hypertension by using perilipin-deficient
mice. Even though Perilipin-/- mice resemble the obese state as they
have increased PVAT basal lipolysis, angiotensin II secretion, macro-
phage infiltration and oxidative stress, they have reduced PVAT mass.
Their dysfunctional PVAT is accompanied by undesirable contraction
and vasoconstriction of aortic/mesenteric arteries and structural
damage of endothelial and smooth muscle cells, indicating that
dysfunctional PVAT may promote atherosclerosis development.
The phenotypic differences between the PVAT depots (i.e. the WAT-
like abdominal PVAT and the BAT-like thoracic PVAT) may contribute
to differences in atherosclerosis susceptibility among the vessels that
these specific PVAT depots surround. Both abdominal PVAT and
thoracic PVAT act as a buffer against toxic levels of fatty acids in the
arterial circulation, but abdominal PVAT clears fatty acids by storing
fatty acids in triglycerides whereas thoracic PVAT does this via
inducing thermogenesis (Fig. 1). Expression of inflammatory genes
and markers of immune cell infiltration (i.e. macrophages and T cells)
are higher in abdominal PVAT than in thoracic PVAT (Padilla et al.,
2013). Abdominal WAT-like PVAT may thus contribute to athero-
sclerosis development whereas thoracic BAT-like PVAT may protect
against atherosclerosis development. Indeed, it has recently been
shown that impaired thermogenesis in PVAT leads to atherosclerosis
development (Chang et al., 2012). In this study, smooth muscle cell-
specific peroxisome proliferator-activated receptor (PPAR) γ-deficiency
led to loss of PVAT and resulted in impaired intra-vascular thermo-
genic capacity and increased atherosclerosis. Cold exposure inhibited
atherosclerosis development and improved endothelial function in
mice with intact PVAT but not in the smooth muscle cell-specific
PPARγ-deficient mice as a result of impaired lipid clearance (Chang
et al., 2012). Thus, functional adaptive thermogenesis in PVAT could
protect against atherosclerosis development. However, it is likely that
obesity leads to whitening and reduced thermogenesis in BAT-like
PVAT, which promotes atherosclerosis development.
Overall, PVAT has beneficial effects on vessel function under
healthy conditions because it has vaso- relaxing effects and a fatty
acid-buffering capacity. In obesity, this adipose tissue depot becomes
dysfunctional and has net vasoconstrictive effects. Dysfunctional PVAT
releases elevated levels of disadvantageous pro-inflammatory adipo-
kines that contribute to atherosclerosis development by acting directly
on the vascular wall. The thermogenic capacity of PVAT is reduced, as
obesity likely induces whitening of BAT-like PVAT.
7. Therapeutic implications
Obese individuals exhibit elevated plasma triglyceride levels and
increased systemic inflammation, both of which contribute to athero-
sclerosis development. Hence, approaches to attenuate atherosclerosis
in obesity should aim at reducing plasma triglyceride levels and
lowering inflammation. To achieve this, the distinct properties of
different adipose tissue depots could be specifically targeted.
Although we will mainly exploit the possibilities to target certain
properties of WAT and BAT, the strategies also hold true for PVAT,
depending on whether it has a more WAT- or more BAT-like
phenotype.
7.1. Triglyceride-lowering strategies
7.1.1. Lipid storage in WAT
One therapeutic approach to reduce plasma triglyceride levels by
targeting WAT could be to stimulate lipid storage instead of lipid
release into the circulation (Okuno et al., 1998). As energy overload in
white adipocytes leads to hypertrophy, insulin resistance and inflam-
mation in WAT, healthy expansion of white adipocytes should be
achieved while maintaining insulin sensitivity. A well-known class of
compounds that promotes healthy lipid storage are the insulin-
sensitizing agents to which the thiazolidinediones (TZDs) and metfor-
min belong. TZDs are PPARγ agonists that stimulate insulin sensitivity,
adipocyte differentiation and fat storage (Yamauchi et al., 2001).
Indeed, the TZD rivoglitazone lowers plasma triglycerides, total
cholesterol and fatty acids and reduces atherosclerosis in mice
(Hiuge-Shimizu et al., 2011). In humans, the TZD pioglitazone
decreases triglycerides, carotid intima–media thickness (Mazzone
et al., 2006) and atheroma volume in a coronary artery (Hanefeld,
2009; Nissen et al., 2008; Park et al., 2011). Metformin increases
insulin sensitivity and is widely used as a glucose-lowering agent in the
treatment of type 2 diabetes (Goodarzi and Bryer-Ash, 2005). It is
thought to act by activating 5' adenosine monophosphate-activated
protein kinase (AMPK), of which activation and phosphorylation are
elevated in WAT upon metformin treatment (Boyle et al., 2011).
Interestingly, metformin also lowers plasma triglycerides and VLDL-
cholesterol (Salpeter et al., 2008), probably via BAT activation
(Geerling et al., 2014), which might account for its cardioprotective
effect in obese patients (UKPDS, 1998). Conclusive evidence for an
effect of metformin on atherosclerosis development is currently studied
in clinical trials.
Promoting lipid storage in WAT also has disadvantages. Although
circulating lipid levels drop, the lipids residing in WAT can lead to
lipotoxicity. Besides, insulin-sensitizing agents not only affect adipose
tissue but also other tissues such as the heart by overloading them with
fatty acids, which has detrimental effects. TZDs have adverse side
effects that limit their use in the clinic (Cariou et al., 2012; Wang et al.,
2016). For instance, rosiglitazone is associated with increased risk of
myocardial infarction (Nissen and Wolski, 2007), but the reason for
these differential effects on cardiovascular outcomes remains unde-
fined (Cariou et al., 2012; Goldberg et al., 2005; Khan et al., 2002).
Together, these drawbacks hold back the use of TZDs to combat
atherosclerosis.
7.1.2. Lipid combustion by BAT
Apart from targeting WAT, a therapeutic approach to reduce
plasma triglyceride levels could be to increase combustion of fatty
acids by BAT and thereby decrease plasma lipid levels. Activation of the
β3-adrenergic receptors is the most well-known and potent way to
induce thermogenesis and lipid combustion (Cannon and Nedergaard,
2004; Cypess et al., 2015) and β3-adrenergic receptor agonists such as
CL-316243 potently induce lipid uptake by BAT (Berbée et al., 2015).
In humans, cold (van der Lans et al., 2013; Yoneshiro et al., 2013),
activation of transient receptor potential channels by capsinoids
(Yoneshiro et al., 2012) and thyroid hormones (Broeders et al., 2016;
Doniach, 1975) have been demonstrated to activate BAT. To date, it
has not been established that BAT activation lowers plasma triglyceride
levels in humans, likely because most studies have applied cold
exposure that increases hepatic VLDL-triglyceride production in addi-
tion to enhancing triglyceride clearance (Hoeke & Nahon et al.,
unpublished). In preclinical studies, many compounds have been
identified to activate BAT. Among these, rimonabant (Boon et al.,
2014), metformin (Geerling et al., 2014), GLP1 receptor activation
(Kooijman et al., 2015) and salsalate (van Dam et al., 2015) also reduce
plasma triglycerides. Since all of these pharmacological strategies also
lower triglycerides in humans, BAT activation may therefore be a
promising treatment option to reduce atherosclerosis.
7.1.3. Beiging of WAT
An alternative therapeutic approach is to induce the formation of
beige adipocytes in WAT. Although it has not been demonstrated to date
(Bartelt and Heeren, 2014), beige adipocytes probably also use triglycer-
ides for nonshivering thermogenesis like classic brown adipocytes do.
The fact that fatty acid uptake in beige WAT upon β3-adrenergic
stimulation increases while the WAT depots shrink (Berbée et al.,
2015) indicates that beige adipocytes do combust triglycerides. Thus,
beiging of WAT likely contributes to the lowering of plasma triglyceride
levels, ultimately resulting in reduced atherosclerotic development.
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Beiging of WAT is typically induced by cold and catecholamine
stimulation (Berbée et al., 2015; Kuji et al., 2008; Yamaga et al., 2008),
but many other stimuli that promote a beige phenotype are rapidly
being discovered and include pharmacological activation of β3-adre-
nergic receptors (Berbée et al., 2015; Cypess et al., 2015), lactate
(Carriere et al., 2014), gut microbiota (Chevalier et al., 2015; Suarez-
Zamorano et al., 2015), thyroid hormone (Lin et al., 2015), glucagon-
like peptide 1 receptor (GLP1R) activation (Kooijman et al., 2015),
fibroblast growth factor (FGF) 21 (Fisher et al., 2012), bone morpho-
genetic protein (BMP) 4 (Qian et al., 2013) and BMP7 (Boon et al.,
2013). Furthermore, various components of the immune system have
been implicated to promote beiging, such as macrophages (Fabbiano
et al., 2016; Nguyen et al., 2011), eosinophils (Qiu et al., 2014) and
ILC2s (Brestoff et al., 2015; Lee et al., 2015) (reviewed in van den Berg
et al., 2016). Several cytokines were identified to be involved in the
underlying mechanisms and recent evidence also points towards a
prominent role for interferon regulatory factors in the regulation of
beiging (Kong et al., 2014; Kumari et al., 2016). Non-endogenous
compounds that induce beiging include AMPK activation (Wang et al.,
2015), inhibitors of Notch signalling (Bi et al., 2014) as well as PPARγ
and PPARα agonists. It must be noted however, that many studies
identifying beiging agents have not reported the effects of the com-
pound on possible loss of insulation, for example upon alterations in
skin or fur. Therefore, the possibility exists that the beiging observed is
(partly) a consequence of increased heat loss rather than a direct effect
of the agent. Moreover, the metabolic effects observed upon treatment
with a beiging compound may not necessarily be caused by beiging and
to verify this, future experiments into beiging agents should include
Ucp1-/- mice and/or thermoneutrality (Nedergaard and Cannon,
2014).
More insight into the formation of beige adipocytes would also help
to develop beiging strategies. It was long thought that in contrast to
white adipocytes, beige adipocytes are derived from precursor cells that
have a gene expression profile similar to muscle, including the
expression of the muscle differentiation factor Myf5 (Timmons et al.,
2007). However, the current model of the differentiation process seems
more complex as Myf5+ cells can also differentiate into white adipo-
cytes (Sanchez-Gurmaches et al., 2012). More specific factors that
mark brown/beige adipogenesis (i.e. the transcription factor Ebf2)
(Wang et al., 2014) are presently being discovered. But then again, how
exactly beige adipocytes develop remains elusive as investigating this
requires cutting-edge labelling strategies and has yielded dissimilar
conclusions so far (Sanchez-Gurmaches et al., 2016). Gaining a better
understanding of adipocyte development is a prerequisite for the
development of compounds that promote beige adipocyte differentia-
tion and is under investigation.
7.1.4. Lipolysis in WAT and BAT: a double-edged sword
Intracellular lipolysis plays a crucial role in both WAT and BAT,
however the effects on plasma triglyceride levels are opposite. Lipolysis
in WAT increases fatty acid release which can lead to hypertriglycer-
idemia, while lipolysis in BAT promotes combustion of fatty acids to
generate heat, which can lower plasma triglyceride levels. To decrease
triglyceride levels and thereby atherosclerosis, a method to induce or
increase lipolysis specifically in BAT is desirable. Alternatively, intra-
cellular lipolysis in WAT and BAT should be balanced in such a way
that fatty acids released by WAT are burned by BAT instead of being
used for hepatic VLDL-triglyceride production. Increased release of
fatty acids by WAT upon treatment with a β3-adrenergic receptor
agonist can indeed be balanced by increased fatty acid combustion in
BAT and beiging of WAT, evidenced by decreased plasma triglycerides
and increased fatty acid uptake in WAT and BAT (Berbée et al., 2015).
Nevertheless, the presence of the β3-adrenergic receptor in the
cardiovascular system (Dessy and Balligand, 2010) is a drawback for
the clinical use of these agonists. Therefore, novel ways to specifically
target brown and beige adipocytes are warranted.
7.2. Anti-inflammatory strategies
Although studies on immune cells in BAT and PVAT are scarce,
immune cells and cytokines are abundant in all WAT depots and may
be causally related to the negative effects of obesity, including athero-
sclerosis. The inflammatory cytokines released by adipose tissue in
obesity contribute to obesity-associated systemic inflammation, but
their exact mechanisms of action in inflammation-induced athero-
sclerosis during obesity remain unknown (Berg and Scherer, 2005) and
contradictory results from clinical studies also impede the development
of cytokine inhibitors. For example, anti-TNF therapy did not improve
the clinical condition of patients with heart failure (Chung et al., 2003;
Mann et al., 2004), but reduced the incidence of cardiovascular events
in rheumatoid arthritis patients (Jacobsson et al., 2005).
Increasing levels of the anti-inflammatory adipokine, adiponectin,
is a promising approach to reduce obesity-induced inflammation and
strategies to boost adiponectin levels or receptor activity are under
investigation (Yamauchi and Kadowaki, 2008). Although targeting
adiponectin and its receptors has been beneficial in metabolic experi-
mental studies, adiponectin-based drug development has not yielded
any clinical applications yet.
Taking into account the wide spectrum of inflammatory cytokines
that are elevated in obesity, targeting a single cytokine might not be
efficient to reduce systemic inflammation and ways to manage the
overall metabolic inflammation should be considered. In this light,
salicylates, such as salsalate, are favourable as they inhibit NF-κB and
thereby transcription of many inflammatory cytokines (Shoelson et al.,
2003). Indeed, salicylates were shown to lower overall inflammation in
WAT (van Dam et al., 2015) and to stabilize pre-existing atherosclero-
sis (de Vries-van der Weij et al., 2010).
8. Conclusion
Taken together, WAT, BAT and PVAT play important albeit tissue-
specific roles in the development of atherosclerosis. In healthy lean
individuals, WAT functions as a lipid sink to keep the vessels clean.
Active BAT combusts lipids to generate heat and therefore takes up
triglyceride-derived fatty acids from the blood, resulting in cholesterol-
rich remnants that are cleared by the liver. PVAT has properties of both
BAT and WAT, since it is capable of storing and combusting lipids and
thus has fatty acid-buffering properties. In obesity, increased lipolysis
from WAT leads to hypertriglyceridemia, BAT is inactivated and PVAT
becomes dysfunctional, all of which contributes to atherosclerosis
development. On top of that, the balance of inflammatory cytokines
and adipokines released by WAT and PVAT shifts towards a more pro-
inflammatory equilibrium as a consequence of lipid overflow in obesity.
The immunomodulatory properties of this array of pro-inflammatory
factors further promotes atherosclerosis development.
To reduce atherosclerosis risk in obese individuals, treatment
should focus on the distinct properties of WAT, BAT and PVAT to
reduce plasma triglyceride levels and systemic inflammation. The most
favourable approach to eliminate triglycerides is by increasing combus-
tion of fatty acids in BAT, thoracic PVAT and beige adipocytes in WAT.
Combining this with anti-inflammatory therapies to restrain systemic
and adipose tissue inflammation currently seems the most promising
strategy to constrain atherosclerosis (Fig. 1).
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